Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome
Authors:
Open Access
Abstract
BACKGROUND: The diagnosis and classification of myelodysplastic syndromes (MDS) is based on cytomorphology (CM) and cytogenetics (CG). Multiparameter flow cytometry (MFC) may add important diagnostic information.METHODS: To evaluate the potential role of MFC in the diagnostic setting of MDS, the authors analyzed the results from 1013 patients with suspected MDS by using CM, CG, and MFC in parallel.RESULTS: Concordance between CM and MFC was 82% for diagnostic results in 788 patients who had unequivocal CM results. An additional 225 patients had only minor dysplastic features identified by CM, including 51 patients (22.7%) who had clear evidence of MDS by MFC. Twelve patients who had no indication of MDS identified by CM had MDS‐typical CG aberrations; in 6 of those patients (50%), MFC revealed MDS characteristics. In another 11 of 23 patients (47.8%) who had minor dysplastic features identified by CM and MDS‐typical CG aberrations, MFC revealed MDS characteristics. The percentages of blasts determined by CM and by MFC were strongly correlated (P < .001). The frequency of aberrantly expressed antigens differed significantly between patients rated by CM as MDS (highest frequencies), suspected MDS, and no MDS (lowest frequencies). In various patients, MFC identified MDS‐typical aberrant antigen expression in cell compartments that were not rated dysplastic by CM. The numbers of aberrantly expressed antigens were correlated with International Prognostic Scoring System scores and overall survival.CONCLUSIONS: The current analysis clearly demonstrated an increased diagnostic yield with MFC when added to CM and CG in patients with suspected MDS. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 34 references indexed in Scilit:
- Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromesHaematologica, 2009
- Cytogenetic features in myelodysplastic syndromesAnnals of Hematology, 2008
- Proposals for standardized protocols for cytogenetic analyses of acute leukemias, chronic lymphocytic leukemia, chronic myeloid leukemia, chronic myeloproliferative disorders, and myelodysplastic syndromesGenes, Chromosomes and Cancer, 2007
- Flow Cytometric Analysis of Monocytes as a Tool for Distinguishing Chronic Myelomonocytic Leukemia From Reactive MonocytosisAmerican Journal of Clinical Pathology, 2005
- Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profileGenes, Chromosomes and Cancer, 2005
- AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypesGenes, Chromosomes and Cancer, 2005
- The WHO classification of MDS does make a differenceBlood, 2004
- Immunophenotypic characterization of myelopoiesis in early and late myelodysplastic syndromes: Use of CD44 as an aid in early diagnosisCytometry, 2002
- Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: A detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24‐color FISHGenes, Chromosomes and Cancer, 2002
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982